Hematologic Oncology

Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.

A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.

Ropeginterferon alfa-2b produced durable complete hematologic responses without phlebotomy and showcased a consistent safety profile in Japanese patients with polycythemia vera, according to findings from a phase 2 study (NCT04182100) presented during the 2022 EHA Congress.

The FDA has accepted a priority review of a biologics license application for omidubicel as a treatment for patients with blood cancers in need of allogenic hematopoietic stem cell transplant.

Expert panelists review the role of the microbiome in the context of hematopoietic stem cell transplantation and steroid-refractory acute GVHD.

Key opinion leaders highlight the value of clinical trials and share their perspective on enrolling patients in the setting of acute GVHD.

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.

A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.

Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.

The addition of zilovertamab to ibrutinib will be compared with ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma as part of the phase 3 ZILO-301 trial.

The addition of pembrolizumab to belantamab mafodotin resulted in a higher overall response rate in patients with relapsed/refractory multiple myeloma than what has been observed with the antibody-drug conjugate alone, according to results from the phase 1/2 DREAMM-4 trial.

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

Comprehensive discussion on the treatment options available for patients diagnosed with steroid-refractory acute GVHD.

A brief review of the evolving utilization of biomarker testing in acute graft versus host disease, particularly for prognostic evaluation.

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Judith Karp, MD, Azra Raza, MD,, and Michelle M. Le Beau, PhD, discuss how their gender has shaped their professional lives, from working as some of the only female clinical faculty at their institutions to being compared to their male colleagues and denied opportunities when working independently from men.

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.